12 March 2020
Sofitel Legend Amsterdam The Grand
2019 Presenting Companies
Aelin Therapeutics (BEL)
Aelin Therapeutics will exploit its proprietary Pept-in™ protein knockdown platform as a novel modality in drug development. The company is based on a very comprehensive preclinical package illustrating different applications of the technology (in bacteria, fungi, viruses, cancer cells). The technology is furthermore protected by a strong and growing IP portfolio.
AM-Pharma is a biopharmaceutical company, engaged in the development of novel human alkaline phosphatase therapeutics for unmet needs in severe inflammatory diseases. The Company’s lead programs for this therapeutic enzyme are in Acute Kidney Injury and Inflammatory Bowel Disease.
Amarin Corporation (IRE)
Amarin is a rapidly growing pharmaceutical company focused on therapeutics to improve cardiovascular health. Vascepa® (
Artios Pharma (UK)
Since its foundation Artios has grown into a leading biotech company with an exciting pipeline of assets, a world class R&D team with a strong track record in translating DDR and other oncology projects from research to the clinic, and an enviable cash position following two successful fundraises from high calibre investors.
Arvelle Therapeutics (SWZ)
- Arvelle was formed with the mission of bringing innovative solutions to patients suffering from CNS disorders.
- Arvelle is responsible for the development and commercialization of cenobamate, an investigational antiepileptic drug, in the European market.
- Arvelle will be based in Switzerland
Atlantic Therapeutics (IRE)
A high growth, commercial-stage company that develops systems, software and mobile apps to treat conditions of the pelvic floor muscles and nerves, including incontinence and sexual health. Atlantic Therapeutics’ vision is to enable millions of people each year to restore their pelvic floor, and thereby restore their control, confidence and active lifestyle.
Binx Health (UK)
binx is improving sexual wellness through new delivery methods that prioritize clinical integrity, consumer privacy and convenience. We provide first of its kind clinical point-of-care and digital-online STI testing programs in a clinically-relevant and commercially overlooked markets that include evidence-based STI testing, counseling and treatment to increase screening and reduce infections.
Cardior Pharmaceuticals (GER)
Cardior is a privately held biopharmaceutical company founded by Prof. Thomas Thum out of the Hannover Medical School. The company is dedicated to becoming world-leader in design, research and development of non-coding RNA-based therapeutics for cardiovascular diseases. Cardior aims to market its products in collaboration with a strategic pharma-partner after clinical validation.
Celyad is a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell-based therapies. Celyad’s CAR-T cell platform has the potential to treat a broad range of solid and hematologic tumors. Its lead oncology candidate, CYAD-01, is currently being evaluated in a Phase I dose escalation clinical trial.
CiMaas is a cell therapy company (2015) focusing on making use of the immune system to treat metastatic cancer, aiming at cure with low side effects to realize high quality of life in patients with different types of cancer.
The products under development- i.e in clinical studies – are based on >18 years of pre-clinical research at the University of Maastricht and the Maastricht University Medical Center, The Netherlands mainly guided by the founders of CiMaas, Dr WTV Germeraad and Prof Dr GMJ Bos.
Eloxx Pharmaceuticals (ISR)
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have short half-life messenger RNA that produce truncated, nonfunctional proteins, accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 2,000 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and enabling protein synthesis to continue through the premature stop codons to restore protein functionality. Eloxx’s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis cystinosis. ELX-02 has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA. with R&D operations in Rehovot, Israel.
eTheRNA is a clinical stage immunotherapy company developing mRNA based therapeutic products for the treatment of cancer. To date the Company has completed 4 clinical studies and has 2 studies underway currently. The company has built a new GMP facility which also provides contract manufacturing services.
Evotec AG (GER)
Evotec is a drug discovery company focused on rapidly progressing innovative product approaches with its customers. It operates worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target identification to IND-enabling studies and high-end CMC (Chemistry, manufacturing and controls). The Company focuses on key therapeutic areas including neuronal diseases, diabetes and diabetic complications, oncology, pain, anti-infectives, respiratory and fibrosis.
For additional information please go to www.evotec.com.
Founded in 2006 EyeSense AG is a spin off venture from Novartis AGs eye care company CIBA Vision. The Company has developed a unique and revolutionary photometric glucose sensor technology which has the potential to transform existing measurement techniques. The sensor is placed at the tip of a tiny optical fiber which is inserted under the skin of the abdomen or the upper arm. Clinical trials have demonstrated a superior accuracy and long-term stability of the new glucose sensor technology. This will allow entry into the very lucrative emerging and growing glucose monitoring market (CGM).
Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Galapagos’ pipeline comprises Phase 3 through to discovery programs in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications. Our target discovery platform has delivered three novel mechanisms showing promising patient results in, respectively, inflammatory diseases, idiopathic fibrosis and atopic dermatitis. Galapagos is focused on the development and commercialization of novel medicines that will improve people’s lives. The Galapagos group, including fee-for-service subsidiary Fidelta, has approximately 578 employees, operating from its Mechelen, Belgium headquarters and facilities in the Netherlands, France, and Croatia. More information at www.glpg.com.
GTX medical (NL)
GTX Medical (Eindhoven, The Netherlands; Lausanne, Switzerland) is a clinical-stage medical device company developing a new therapy to help paralyzed people walk again, using a new form of Spinal Cord Stimulation: Targeted Epidural Spinal Stimulation (TESS), in combination with intensive rehabilitation training. GTX medical is a spinout of the group of Prof Courtine at the Center for Neuroprosthetics at the Swiss Federal Institute of Technology Lausanne (EPFL).
ImCheck Therapeutics is a Marseille-based, privately-held biotech company developing nenext-generationmmuno-modulatory antibodies acting on both adaptive and innate immunity for the treatment of cancer and other immune related diseases.
With a “precision medicine-based” translational approach and several established academic collaborations, ImCheck is uniquely positioned to develop the right therapy for each patient.
Immunic AG (GER)
Kiadis Pharma (NL)
Kiadis allodepleted T-cell immunotherapy product can make haploidentical hematopoietic stem cell transplantations safer and more effective. Phase 2 data with lead product ATIR given after HSCT in blood cancer patients shows a clinically relevant improvement over literature for the Baltimore protocol, without risk of severe chronic Graft versus Host Disease.
Kuros Biosciences (SWZ)
Kuros is a company with an initial focus on bone repair and regeneration (orthobiology). The Company has developed commercial-stage products and a pipeline of clinical and pre-clinical product candidates at various stages of development. The most advanced orthobiology programs are targeting commercially attractive opportunities in the spinal field. Our initial focus on the spinal field is due to the fact that it represents approximately 50% of the bone graft substitute market. In addition to many years of substantial work in the preclinical setting, Kuros has enrolled over 600 patients in multi-national clinical trials and generated promising data supporting the safety and efficacy of its product candidates in a number of indications.
Lumeon Care Pathway Management platform enables healthcare organizations orchestrate and automate systems, processes and teams – uniting patients with care teams: improving patient experience; providing better, more consistent outcomes; ensuring care is efficiently coordinated in real-time. CPM enables digital control of care delivery models, maximizing resource utilization, reducing cost and minimizing variation.
Medication errors in hospitals and healthcare institutions are accidents caused by human errors. MedEye prevents those errors by automating checks and the bedside – saving time for nurses and improving quality. Since first full implementation in 2016, MedEye has spread to 4 markets and helped stop over 100.000 medication errors.
Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics with the goal of treating and potentially curing cancer patients. Our most advanced development programs use the Biclonics® format. Biclonics® are capable of simultaneously attacking tumors in multiple ways. For example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways
Miracor Medical (BEL)
Miracor Medical is an advanced clinical stage interventional cardiology company Miracor aims at the massive unmet need of Heart Failure Prevention, by reducing the infarct size in patients who suffer an acute myocardial infarct. Miracor is headquartered in Awans, Belgium and currently employs 20 full-time equivalents.
Nordic Nanovector (NRW)
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. Further information can be found at www.nordicnanovector.com
Orphazyme A/S (DEN)
Orphazyme’s current clinical programs investigate arimoclomol as a treatment for four protein-misfolding indications: The protein-aggregation diseases Amyotrophic Lateral Sclerosis (ALS) and sporadic Inclusion Body Myositis (sIBM), and the lysosomal storage diseases Niemann-Pick disease Type C (NPC) and Gaucher disease. The new molecular entity (NME) program focuses on the development of new molecules as a treatment for rele- vant protein-misfolding diseases.
Oryzon (ORY.MC) is one of the most liquid companies of the Spanish stock market. Oryzon is clinical stage Biopharmaceutical and the European champion in Epigenetics. In 2015-2016, the company raised €32M, with additional Pipes in 2017 (€18.2M) and 2018 (€13M) where the company incorporated specialized investors from US and Europe. Oryzon’s competitive Epigenetic Platform develops innovative drugs for serious diseases with strong unmet medical need in cancer and CNS. Oryzon’s pipeline includes inhibitors against Histone demethylases, particularly in LSD1. It is currently running 5 clinical Phase IIa trials with two different assets.
OxThera AB (SWE)
OxThera is developing a novel treatment, Oxabact, for Primary hyperoxaluria (PH), a fatal ultra-orphan disease in children, and where there are currently no available therapies. The company has initiated a pivotal Phase III study in PH with Oxabact in order to stop and/or delay disease progression. Oxabact holds orphan drug designations in the EU and the US for the treatment of PH, and in the EU for treatment of Short Bowel Syndrome (SBS).
Pharvaris is a preclinical stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients for use as an alternative to injected therapies for hereditary angioedema (HAE) and other B2 receptor-mediated indications. The company reunites the core team responsible for the discovery and approval of the HAE treatment FIRAZYR icatibant. PHA121 is a potent and orally available novel small molecule targeting this clinically proven therapeutic target, with clinical entry anticipated in the near-term.
reMYND develops cures for Type 1&2 Diabetes, Alzheimer’s disease, Huntington’s disease, ALS and other orphan diseases caused by protein misfolding. The two lead programmes are less than 12 months pre-IND: the diabetes programme in collaboration with Novo Nordisk and the Alzheimer programme fully under own control.
Sequana Medical (CH)
Sequana Medical is a commercial stage medtech and an innovator in the management of liver disease, heart failure and other fluid imbalance disorders. Cirrhotic-ascites is a large market and forecast to grow significantly due to the increasing prevalence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
SNIPR Biome (DEN)
SNIPR BIOME is engaged in the discovery and development of CRISPR/Cas-based drugs, using its proprietary and patent-protected CRISPR/Cas platform. SNIPR BIOME is pioneering a novel use of CRISPR/Cas technology to selectively and precisely eradicate target bacteria, while leaving the rest of the patient’s microbial community intact.
Vetex Medical (IRE)
Vetex Medical is a privately-held early stage company based in the strong Med Tech Cluster in Galway Ireland. Established in 2016, the company is focused on making venous clot removal predictable, quick and cost-effective. The company’s first thrombectomy product treats deep vein thrombus by removing large volumes of clot in a single session, without use of thrombolytic drugs.
Vivasure Medical (IRE)
In percutaneous endovascular procedures such as heart valve replacement and aortic aneurysm repair, large arteriotomies are created. Existing percutaneous closure technologies are complex to use, are associated with significant complications and leave permanent implants in the vessel. Vivasure solves this problem with a safe, effective and easy-to-use device.
uniQure is delivering on the promise of gene therapy, single treatments with potentially curative results. We have developed a modular technology platform to rapidly bring new disease-modifying therapies to patients with severe genetic diseases.
We are advancing a focused pipeline of innovative gene therapies and have established clinical proof-of-concept in our lead indication, hemophilia B, and preclinical proof-of-concept in Huntington’s disease. Our pipeline of adeno-associated virus (AAV)-based gene therapies has been developed using an innovative technology platform, supported by industry-leading proprietary commercial-grade manufacturing capabilities.
Xeltis ETR technology has been tested in various cardiovascular feasibility clinical trials (Fontan, Atrial patch and Pulmonary valve). Xeltis closed a Series B financing and an extension based on these first promising clinical results. In 2017 the company closed a round of 45 M to further expand applications in the cardiovascular space.
Zealand Pharma (DEN)
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi and Boehringer Ingelheim and a pipeline of internal product candidates focusing on specialty gastrointestinal and metabolic diseases.